Abstract:This translational study explored the evolving cEV signature in critically‐ill COVID‐19 patients, from hospital admission to death, and compared it to reference non‐COVID‐19 healthy subjects, shedding light on its potential role in disease progression and death. Specifically, we unravelled that specific cEV subtype levels are released by circulating and vascular cells providing precise information on the pathophysiological processes during COVID‐19‐associated clinical deterioration and associate with their survival time. Changes in distinct cEV subpopulations may discriminate those patients more predisposed to poor outcomes highlighting the importance of cEVs as tracers of disease evolution. Background The global pandemic of coronavirus disease 2019 (COVID‐19) represented a major public health concern. Growing evidence shows that plasma of COVID‐19 patients contains large numbers of circulating extracellular vesicles (cEVs) that correlate with disease severity and recovery. In this study, we sought to characterize the longitudinal cEV signature in critically ill COVID‐19 patients during hospitalization and its relation to mortality risk. Methods cEVs were quantitatively and phenotypically analysed in hospitalized non‐surviving COVID‐19 patients at baseline (n = 42) and before exitus (n = 40) and in 40 healthy volunteers as a reference group by high sensitivity nano flow cytometry using specific markers for parental cell sources and activation. Results Levels of cEV subtypes differed between patients with severe COVID‐19 and healthy subjects, specifically those from platelets and endothelial, inflammatory and viral infected cells, which associate to high mortality risk. In the longitudinal analysis from baseline to the time point immediately preceding death, no changes were found for platelet, pan‐leukocyte, and lung epithelial cell‐shed cEVs, while endothelial cell releases of EVs (eEVs) significantly differed. Vascular endothelial growth factor receptor 2‐positive eEVs were significantly increased before death compared to admission whereas endoglin and E‐selectin‐containing eEVs did not change. Conversely, lymphocyte (lEV), monocyte, macrophage, pericyte and progenitor cell‐derived cEVs displayed significant reductions before exitus. Noteworthy, levels of CD45+/CD3+‐lEVs were significantly associated to the patient's survival time. Conclusions An evolving cEV profile able to discriminate prompt risk of death during hospitalization has been defined suggesting a role for circulating and vascular cell‐derived EVs in COVID‐19 pathogenesis.

Blood CD45+/CD3+ lymphocyte‐released extracellular vesicles and mortality in hospitalized patients with coronavirus disease 2019